Nematode parasites infect~2 billion people world-wide. Infections are treated and prevented by anthelmintic drugs, some of which act on nicotinic acetylcholine receptors (nAChRs). There is an unmet need for novel therapeutic agents because of concerns about the development of resistance. We have selected Asu-ACR-16 from a significant nematode parasite genus, Ascaris suum, as a pharmaceutical target and nicotine as our basic moiety (EC 50 6.21 ± 0.56 mM, I max 82.39 ± 2.52%) to facilitate the development of more effective anthelmintics.
Introduction
Our research has had a focus on nicotinic acetylcholine receptors (nAChRs) of parasitic nematodes because they are target sites that bind a major class of anthelmintic drugs. nAChRs are pentameric ligand-gated ion channels involved in synaptic transmission in the nervous systems of both vertebrates and invertebrates (Taly et al., 2009 ); these receptor channels also serve other functions including paracrine functions in non-excitable tissues (Proskocil et al., 2004) . The nAChRs are activated by the ligand agonists: acetylcholine (ACh), nicotine and structurally related derivatives, that produce opening of their transmembrane ionchannel and flux of sodium, potassium and sometimes calcium ions across the membrane.
The agonist-binding sites of nAChRs have been well studied by photolabeling, mutagenesis and electrophysiology (Arias, 2000) .
Our understanding of ligand-receptor interactions has improved following co-crystal structure studies of invertebrate acetylcholine binding proteins (AChBPs) with cholinergic ligands (Sixma and Smit, 2003; Rucktooa et al., 2009) . AChBPs are homologs of the extracellular agonist-binding site domain of nAChRs that share 20e24% nucleotide sequence identity with the extracellular domain of AChRs (Blum et al., 2010) . The agonist-binding site of nAChRs is in the extracellular domain at the interface between the principal subunit (that is an alpha subunit with vicinal cysteines) and the adjacent complementary subunit. Five aromatic amino acids in the agonist-binding site are highly conserved in nAChRs, some of which contribute to the cation-p interactions with the cationic nitrogen in agonists (Dougherty, 2013) . Another feature of nAChR agonists is the hydrogen bond acceptor, which is about 4e6 Å from the cationic nitrogen. Based on the high-resolution structures of AChBPs, the hydrogen bond acceptor of the agonist is stabilized by a water molecule, which interacts with the carbonyl or the amide backbones of two less conserved residues (L102 and M114) on loop E of the complementary subunit through three hydrogen bonding interactions (Van Arnam and Dougherty, 2014) .
Ascaris, a genus of clade III nematode parasites, are gastrointestinal roundworms that infect humans, pigs and other animals worldwide (Taylor et al., 2016) and have been estimated to cause more than 1.2 billion human infections (de Silva et al., 2003) . In developing countries, the control of Ascaris infection relies on the limited number of available anthelmintic drugs. Drug resistance in various nematodes has been reported following frequent use of anthelmintics (Garcia et al., 2016) . There is an unmet need for novel effective drugs which would overcome development of resistance to existing anthelmintics.
The ACR-16 nicotinic acetylcholine receptor of Ascaris suum (Asu-ACR-16) is a nematode homopentameric receptor, which resembles vertebrate a7 nAChRs (Mongan et al., 2002) . Asu-ACR-16 is widely distributed in A. suum tissues but its physiological function remains to be determined Zheng et al., 2016) . As one of the recently characterized nematode parasitic nAChRs, Asu-ACR-16 is pharmacologically different to its host a7 nAChR and may be exploited as an anthelmintic drug target to counter resistance to cholinergic anthelmintics directed at other pharmacological types of nAChR (Holden-Dye et al., 2013; Zheng et al., 2016) .
The agonist-binding site of Asu-ACR-16 receptors can be predicted by homology modeling using the human a7 nAChR chimera as structural template, which shares 38% identity and 73% similarity in amino acid sequence. Five conserved aromatic residues and two hydrogen-bond interacting residues have orientations very close to corresponding residues in other nAChRs, facilitating our investigation of drug-receptor interactions of the Asu-ACR-16 receptor (Zheng et al., 2016) . We know that the Asu-ACR-16 receptor is sensitive to six nicotinic agonists: nicotine, ACh, cytisine, 3-bromocytisine, epibatidine, dimethyl-4-phenyllpiperazinium iodide (DMPP), but insensitive to other cholinergic anthelmintic agonists . All six of the Asu-ACR-16 agonists share the nicotinic pharmacophore: a cationic nitrogen separated by~5 Å from a hydrogen bond acceptor. Here we use a combination of structural modeling and synthetic strategy based on the nicotinic pharmacophore to explore the pharmacological profiles of nicotine derivatives on the Asu-ACR-16 receptor.
Materials and methods

Homology modeling and docking
The Asu-ACR-16 sequence is available in UniProtKB under the accession number F1KYJ9 (Wang et al., 2011) . Three crystal structures of a human a7 nAChR chimera co-crystalized with ligands of different modes of action were used as templates (Table 1) to build three different bound-form models of the ECD-Asu-ACR-16 (Li et al., 2011; Huang et al., 2013; Zheng et al., 2016) . Smiles strings of nicotine derivatives were obtained from the ZINC website (http:// zinc.docking.org/search/structure) and converted to PDBQT format for our docking studies. Docking of these ligands was performed at the orthosteric ligand-binding sites of agonist-bound, apo (no ligand) and antagonist-bound forms of the ECD-Asu-ACR-16 models using AutoDock Vina Software (Trott and Olson, 2010; Zheng et al., 2016) . We investigated the intermolecular interactions in our models by comparing the intermolecular distances in the crystal structures and our models ( 1 Å difference).
Expression and electrophysiology of Asu-ACR-16 in oocytes
Full length cRNA of Asu-acr-16 and the ancillary gene, Asu-ric-3 (UniProtKB accession number: F1L1D9_ASCSU). were prepared using the previously described methods (Zheng et al., 2016) . A cRNA mixture of 25 ng Asu-acr-16 and 5 ng Asu-ric-3 cRNA in 50 nL RNAse-free water was injected into de-folliculated Xenopus laevis oocytes (Ecocyte Bioscience, Austin, TX, USA). The injected oocytes were incubated in incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 $2H 2 O, 1 mM MgCl 2 $6H 2 O, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin, pH 7.5) at 19 C for 4e8 days, with 100 mM BAPTA-AM added~3 h before recording.
A two-electrode voltage-clamp technique was used to record currents from the Asu-ACR-16 receptor expressed in the Xenopus oocytes. The oocytes were kept in recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl 2 $2H 2 O and 5 mM HEPES, pH 7.3) and clamped to À60 mV. Inward currents were induced by addition of chemicals that acted as agonists that opened the nicotinic ionchannel receptors. An Axoclamp 2B amplifier (Molecular Devices, CA, and USA) was used to record the currents that were acquired with Clampex 9.2 (Molecular Devices, CA, USA) software and analyzed using GraphPad Prism 5.0 (GraphPad Software Inc. CA, USA).
Chemicals used for synthesis
The following chemicals were used for the synthesis of (S)-5-bromonicotine, (S)-5-bromoanabsine and (S)-5-ethynyl-anabsine: 4,4'-di-tert-butyl-2,2'-dipyridyl (dtbpy), copper (II) bromide (CuBr 2 ), 2-methyl-3-butyn-2-ol, triethylamine (Et 3 N) and N,N-diisopropylethylamine (DIPEA) obtained from Sigma-Aldrich (St Louis, MO, USA); di-m-methoxobis (1,5-cyclooctadiene)diiridium(I) ([Ir(COD) (OMe)] 2 ) and methanesulfonato (2-di-t-butylphosphino-2 0 ,4 0 ,6'-tri-i-propyl-1,1'-biphenyl) (2'-amino-1,1'-biphenyl-2-yl) palladium (II) (Pd(PPh 3 ) 2 Cl 2 ) obtained from Strem Chemicals (Newburyport, MA, USA); (S)-nicotine, (S)-anabasine and copper(I) iodide (CuI) obtained from Alfa Aesar (Ward Hill, MA, USA); bis(-pinacolato)diboron (B 2 pin 2 ) obtained from Matrix Scientific (Columbia, SC, USA); (trimethylsilyl)acetylene and di-tert-butyl dicarbonate (Boc 2 O) obtained from Oakwood Products (Estill, SC, USA); dichloromethane (DCM), trifluoroacetic acid (TFA), methanol (MeOH), tetrahydrofuran (THF) and potassium carbonate (K 2 CO 3 ) obtained from Fisher Scientific (Waltham, MA, USA).
General synthetic experiment
All air-sensitive procedures were conducted under an inert atmosphere of a nitrogen-filled dry box or by standard Schlenk techniques. All reactions were performed under an atmosphere of nitrogen unless otherwise stated. All glassware for moisture Table 1 Structural information for the ECD-Asu-ACR-16 and two of its homologous proteins (human a7 nAChR chimera and Lst-AChBP). 
Synthesis of (S)-5-bromonicotine
Synthesis of (S)-5-bromonicotine was carried out following the published procedure (Liskey et al., 2010 ):
2.6. Synthesis of (S)-tert-butyl-2-(pyridine-3-yl)piperidine-1-carboxylate Synthesis of compound -1, (S)-tert-butyl 2-(pyridin-3-yl)piperidine-1-carboxylate, below, was conducted using the following approach.
Boc 2 O (3.30 g, 15.1 mmol, 1.10 equiv) was added to a solution of (S)-anabasine (2.23 g, 13.7 mmol, 1.0 equiv) and Et 3 N (2.10 mL, 15.1 mmol, 1.10 equiv) in THF at 0 C. The reaction mixture was stirred for 10 min and warmed to room temperature. After stirring for 2 h, the mixture was diluted with water, and extracted with EtOAc (3Â). The organic layers were combined, dried over Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (1:1 hexane:EtOAc) to yield compound À1, (S)-tert-butyl 2-(pyridin-3-yl) piperidine-1-carboxylate in 95% yield (3.40 g, 13. (Beng and Gawley, 2011) .
Synthesis of (S)-tert-butyl 2-(5-bromopyridin-3-yl)piperidine-1-carboxylate
Synthesis of compound -2, (S)-tert-butyl 2-(5-bromopyridin-3-yl)piperidine-1-carboxylate from compound À1 was carried out as described below.
In a nitrogen-filled glove box, compound -1 (1.31 g, 5.0 mmol), B 2 pin 2 (1.12 mg, 4.4 mmol), [Ir(COD) (OMe)] 2 (99.5 mg, 0.150 mmol, 0.030 equiv), dtbpy (80.5 mg, 0.030 mmol, 0.060 equiv), and THF (8.0 mL) were combined in a vial. The reaction mixture was then sealed and heated at 80 C for 16 h. After the reaction mixture was cooled to room temperature, the volatiles were removed under vacuum. The residue was dissolved in 50.0 mL of MeOH and 50.0 mL of distilled water followed by CuBr 2 (3.35 g, 15.0 mmol). The flask was then sealed and heated at 80 C for 16 h. The reaction mixture was cooled to room temperature, and 30% NH 4 OH (aq) (20.0 mL) was added to the reaction mixture. The reaction mixture was extracted with EtOAc (3 Â), and the organic layers were combined, washed with brine, and dried over Na 2 SO 4 . The product was purified by column chromatography using silica gel (3:1 hexane:EtOAc) to give compound -2, (S)-tert-butyl 2-(5-bromopyridin-3-yl)piperidine-1-carboxylate in 36% yield (618 mg, 1.80 mmol) as a pale yellow solid. 
Synthesis of (S)-5-bromoanabasine
Synthesis of (S)-5-bromoanabasine, was prepared from compound -2 as described below.
To a solution of compound 2 (93.0 mg, 0.273 mmol, 1.0 equiv) in DCM (5.0 mL), TFA (1.0 mL) was added dropwise. The reaction mixture was stirred at room temperature for 12 h. The mixture was diluted with saturated NaHCO 3 and extracted with EA (3Â). The organic layers were combined, dried over Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (10:1 hexane:EtOAc to 10:1 EtOAc:Et 3 N) to give (S)-5-bromoanabasine in 83% yield (54.4 g, 0.226 mmol) as a pale yellow solid. 
Synthesis of (S)-5-ethynyl-anabasine
Synthesis of (S)-5-ethynyl-anabasine, was prepared from (S)-5-bromoanabasine as described below.
In a nitrogen-filled Schlenk tube, compound 2 (247 mg, 1.02 mmol) in THF (3.0 mL), Pd(PPh 3 ) 2 Cl 2 (143 mg, 0.204 mmol, 0.20 equiv), CuI (39.0 mg, 0.204 mmol, 0.20 equiv), DIPEA (3.0 mL), and trimethylsilylacetylene (0.16 mL, 1.12 mmol, 1.10 equiv) were added. The mixture was stirred at 70 C for 16 h. After cooled to room temperature, the mixture was filtered through a short pad of silica gel and washed with ethyl acetate The filtrate was concentrated and purified by short silica gel column (100:1 hexane:EtOAc to hexane:EtOAc 5:1) to give the crude product, which was used directly for next step.
To a solution of the crude product in DCM (10.0 mL), TFA (10.0 mL) was added. The mixture was stirred at rt for 2 h. All the volatiles were removed under reduced pressure. The crude product was purified by short silica gel column (2:1 hexane:EtOAc to 8:1 EtOAc:Et 3 N).
To a solution of the above crude product in MeOH (10.0 mL), K 2 CO 3 (568 mg, 4.08 mmol) was added. The mixture was stirred at room temperature for 16 h. After filtration and concentration, the product was purified by column chromatography using silica gel (5:1 hexane:EtOAc to 10:1 EtOAc:Et 3 N) to give (S)-5-ethynyl-anabasine in 7% yield (12.8 mg, 0.0714 mmol) as a pale yellow liquid. 
Pharmacological characterization of nicotinic derivatives and data analysis
The aqueous soluble compounds: acetylcholine (ACh), (S)-nicotine, (S)eSIB 1508Y, (S)-1-methylnicotinium, (S)-1'-methylnicotinium, nornicotine, (S)-cotinine, (S)-anabasine, (S, R)-anabasine were dissolved in recording solution at the concentrations described in the results. Non-polar compounds were dissolved initially in DMSO to make 100 mM stock solutions of each. Subsequently they were diluted in recording solution to give a concentration of DMSO of <0.1%. 100 mM ACh was applied first to each oocyte for 10 s to check for robust Asu-ACR-16 expression. In all oocyte recordings the peak current response to 100 mM ACh was used to normalize subsequent current responses in that oocyte. Recording solution was then used to wash out the drug from the oocytes for 3 min prior to next application of drug perfusion.
Nicotine derivatives that elicited inward currents at 100 mM were classed as agonists. To further characterize the nicotine derivative agonists, increasing concentrations of the derivatives were applied for 10 s (3 min wash intervals between drug applications). The resulting dose-response relationships were described by the Hill equation to give estimates of the EC 50 (mM), Hill slope (n H ), maximum response (I max , %) and expressed as mean ± S.E.M.
(N ¼ 5) using GraphPad Prism 5.0 (Graphpad Software Inc. CA, USA). 
Drugs
Results
Ligand-binding sites
Lst-AChBP (PDB code: 1UW6) (Celie et al., 2004) shows 23.33% sequence identity and 64.29% sequence similarity to ECD-Asu-ACR-16 (Fig. S4A) and is the only crystal structure of a protein homologous to Asu-ACR-16 co-crystalized with nicotine to date. The ligand-binding site for agonist is at the interface between the principal side and the complementary side in two adjacent subunits of nAChRs (Li et al., 2011; Rucktooa et al., 2012) .
Nicotine adopts the same binding pose in all five ligand-binding sites in Lst-AChBP pentamer (Fig. 1A) . The pyrrolidine ring of nicotine is oriented toward the basal side of the binding site on the principal subunit, whereas the pyridine ring faces the apical side on the complementary subunit. The protonated nitrogen (N2) in the pyrrolidine ring of nicotine is involved in cation-p interactions, mainly with W143 (on principal subunit) or maybe four aromatic residues in the binding site (principal subunit: Y89, Y185, Y192; complementary subunit: W53) (Fig. 1B) . The N2 is also hydrogenbonded to the hydroxyl moiety of Y89 and W143 carbonyl backbone. Hydrophobic interactions from disulfide-bonded C187 and C188 on loop C stabilize nicotine in the binding pocket. The pyridine ring nitrogen of nicotine (N1) is hydrogen-bonded to a water molecule, which is stabilized by the carbonyl backbone of L102 and M114 amide backbone of the complementary subunit (Fig. 1B) (Celie et al., 2004; Van Arnam and Dougherty, 2014) . Fig. 1C shows the ligand-binding site of the agonist-bound Asu-ACR-16 dimer viewed from the same angle as Fig. 1B . The residues involved in the binding site are highlighted in Fig. 1C and indicated in Fig. S4A by arrows. The interacting residues in the binding site of the agonist-bound Asu-ACR-16 model share similar orientations with those in the binding site of Lst-AChBP. The hydrophobic, hydrogen-bond and van der Waals contacts between nicotine and AChBP were therefore predicted in Asu-ACR-16. Y117, W173, Y214, Y221 from principal and W79 from complementary constitute the aromatic cage, in which W173 contributes most to the cation-p interaction with protonated tertiary amine or tetramethyl ammonium salt of nicotine or its derivatives. The hydroxyl moiety of Y117 and W173 carbonyl backbone are hydrogen-bonded to the protonated tertiary amine or ammonium of the ligand. The carbonyl backbone of N131 and I143 amide backbone from the complementary face have water-mediated hydrogen bond with the pyridine ring N1 of the ligand.
Structural superimposition of the binding-site residues among three different bound forms Asu-ACR-16 show details of conformational changes of residues when the agonist is in the binding pocket of the receptor. Of particular note is the inward movement of vicinal cysteines toward pyrrolidine N2 of nicotine. The antagonist-bound model has less steric hindrance in the open receptor binding site (Fig. 1D) (Huang et al., 2013) .
The human a7 nAChR chimera (PDB code: 3SQ6) (Li et al., 2011) shows 62.98% sequence identity and 80.29% nucleotide sequence similarity with the extracellular domain of human a7 nAChR (UniProtKB accession number: P36544). The residues constituting the ligand-binding site are highly conserved between human a7 nAChR chimera and human a7 nAChR (Fig. S4B) . The crystal structure of human a7 nAChR chimera co-crystalized with epibatidine could be used to study the binding site of agonist-bound human a7 nAChR. Comparison of the binding sites in Lst-AChBP ( Fig. 2A) , human a7 nAChR chimera (Fig. 2B) , agonist-bound Asu-ACR-16 (Fig. 2C ) and apo form of Asu-ACR-16 (Fig. 2D ) reveals that the 5-substituted pyridine derivatives of nicotine would be favorable, with more space for the binding site of the ECD-Asu-ACR-16, but not for the human a7 nAChR. The black dotted arrows mark the likely orientation of the functional group on the 5-pyridine moiety of nicotine ( Fig. 2C and D) . Additionally, our docking results show that the 5-substituted pyridine ring approaches close to the disulfide bonds of Asu-ACR-16 and that the pyrrolidine ring is twisted downward in the binding site (Fig. S5) .
Potency of nicotine derivatives
Initially we tested a range of nicotine analogues (compounds labelled 3e5 & 7e17 in Table 2 , Fig. 3 ) as agonists to further characterize the pharmacological profile of Asu-ACR-16 receptors by measuring agonist EC 50 , I max and n H values. The EC 50 for (S)-nicotine was 6.21 ± 0.56 mM and the I max was 82.39 ± 2.52%, N ¼ 5 (Table 2 ).
(S)-nicotine is a potent agonist of Asu-ACR-16, but can also activate mammalian nAChRs and as an anthelmintic would also cause effects in the host (Chavez-Noriega et al., 1997). As a low-molecularweight and water soluble molecule, (S)-nicotine was selected as our initial lead for further optimization (Bleicher et al., 2003) . Using (S)-nicotine as a pharmacophore and the predicted three-dimensional structures of the Asu-ACR-16 ligand-binding site, we studied structure-activity relationships by measuring the EC 50 , I max and n H values of the nicotine derivatives (Fig. 4, S6 and Table 2 ) on the Asu-ACR-16 receptor. The agonist dose-response relationships for ACh and (S)-nicotine (Fig. 5A) , pyridine substituted nicotine derivatives (Fig. 5B ) and the pyrrolidine substituted nicotine derivatives (Fig. 5C) 
(S)-enantiomers are more potent
We compared the pharmacological profiles of (S)-anabasine and its racemic mixture on Asu-ACR-16 (Fig. S7) . The EC 50 of (S)-anabasine was significantly lower than the EC 50 of its racemic mixture (P < 0.05, N ¼ 5). The I max of (S)-anabasine was slightly higher than that of its racemic mixture (P > 0.05, N ¼ 5). These results are consistent with other published results that illustrate the higher intrinsic activities of (S)-enantiomer nicotine alkaloids rather than their (R)-enantiomer (Cosford et al., 2000) . Therefore, subsequent synthesis of compounds was directed towards preparation of (S)-enantiomers. Table 2 Pharmacological profiles of ACh, nicotine and fifteen nicotine derivatives. Results (mean ± S.E.M.) were expressed as the EC 50 (mM), Hill slope (n H ) and maximum response (I max , %), number of repeats of each agonist experiment (N agonist ). One oocyte was used in each replicate of experiment.
No:
Compound name EC 50 (mM) n H I max (%) N agonist 1: (S)-5-ethynyl-anabasine 0.14 ± 0.01 1.81 ± 0.24 79.33 ± 3.75 5 2:
(S)-5-bromoanabasine 0.32 ± 0.03 4.19 ± 1.58 80.69 ± 2.87 5 3:
(S)eSIB 1508Y 0.37 ± 0.10 0.94 ± 0.04 100.1 ± 4.36 5 4:
5-methylnicotine 0.99 ± 0.17 2.09 ± 0.14 76.05 ± 1.22 5 5:
(S N-methyl anabasine <100 16:
(S)-1-methylnicotinium <100 17:
(S)-cotinine <100
(S) -5-ethynyl-anabasine, (S)-5-bromoanabasine and (S)-5-bromonicotine
Examination of the structures and EC 50 potencies of (S)eSIB 1508Y and (S)-anabasine suggested that a novel compound, (S)-5-ethynyl-anabasine, would yield a more potent agonist. Consequently, it was synthesized, as described in the methods, along with (S)-5-bromonicotine and (S)-5-bromoanabsine that were produced during its synthesis. The three novel synthesized compounds were then tested on the Asu-ACR-16 receptor. The concentration response plots for these compounds revealed that two of the novel compounds, (S)-5-ethynyl-anabasine and (S)-5-bromoanabsine were the most potent agonists tested to date (Fig. 5C & Table 2 ). 
Correlation between affinity and potency among nicotine derivatives
The binding affinities of the selected nicotine derivatives were calculated for ligands docking into the agonist-binding site in the agonist-bound form, the apo (no ligand) form and the antagonistbound form ECD-Asu-ACR-16 models. We examined the relationship between the binding affinities and the observed values of the expressed receptors for the EC 50 (mM) of the nicotine derivatives. There was a positive correlation (þ0.66) between the binding affinity and the EC 50 of the apo form model (P < 0.05) (Fig. 6) ; the correlation with the agonist bound Asu-ACR-16 (0.36) and antagonist bound Asu-ACR-16 (0.46) were smaller and did not reach statistical significance (P > 0.05). The highest correlation with the apo form suggests that this model is more likely to predict the potency of unknown agonists than the other models of the receptor. 
. Pyridine ring substituted derivatives
We studied the effects of functional groups added to the different positions of pyridine moiety of nicotine: the methyl group substituted at the 5-or 6-or N-pyridine moiety of nicotine, and an amino group substituted at the 6-pyridine moiety of nicotine. 5-Methylnicotine was the most potent agonist, while 6-methylnicotine was slightly less potent. 6-AN showed little agonist activity. The electron-donating group of the methyl or the amino at the 5-or 6-pyridine increased the electronegativity and alkalinity of the pyridine N1, and so stabilized the water-mediated hydrogen bond with the carbonyl backbone of N131 and I143 amide backbone from the complementary subunit of the receptor. The lone pair electrons on the pyridine N1 of (S)-1-methylnicotinium were replaced by the methyl group. As a result N1 cannot hydrogen-bond with the carbonyl backbone of N131 and I143 amide backbone from the receptor so that this reduces the intrinsic activity of N-pyridine substituted derivatives. (B) Pyridine ring substituted derivatives. Responses of 30 mM 5-methylnicotine and 100 mM 6-methylnicotine are shown but were not included for fitting the Hill equation to estimate EC 50 , n H and I max correspondingly due to their inhibitory effects at high concentrations.
(C) Pyrrolidine ring substituted derivatives. Response of 300 mM homonicotine is shown but was not included for fitting the Hill equation to estimate EC 50 , n H and I max due to its inhibitory effect at high concentration.
5-substituted pyridine derivatives
Given that the electron-donating groups at the 5-pyridine of nicotine were found to have the highest potency as agonists, the electron-withdrawing groups of acetylene, bromine or aldehyde derivatives at the 5-pyridine position of nicotine were selected for testing. (S)eSIB 1508 was the most potent agonist, while (S)-5-bromonicotine and (S)-nicotine-5-carboxaldehyde were less potent. The extra cavity within the binding site of Asu-ACR-16 agonist-bound and apo model could accommodate the linear acetylene substituent and globular bromine atom at the 5-pyridine ring of nicotine, allowing the ligands to extend into unoccupied space (Fig 2CD, top left quadrants of the binding pocket) . The bent structure of aldehyde appears to be less favored in the binding pocket. Our docking studies show another possible reason for the 5-substituted pyridine derivatives to stabilize Asu-ACR-16. Fig. S5B&C show that the 5-substituted pyridine ring approaches towards the close-in conformation of the vicinal cysteines, which is a typical feature of the activated state of AChRs.
Pyrrolidine ring substituted derivatives
To study the effects of functional groups added to the different positions of pyrrolidine moiety of nicotine, a methyl or ethyl group was added at the N-pyrrolidine moiety of nicotine, and a ketone group was added at the 5'-pyrrolidine moiety of nicotine. The additional methyl group linked to the pyrrolidine N2 of (S)-1'-methylnicotinium produces a quaternary ammonium, which increases the cation-p interaction with the five aromatic residues from the ACR-16 receptor, but increases the steric hindrance around the pyrrolidine N2 making this compound stereochemically unfavorable. The increased steric hindrance due to the ethyl group at pyrrolidine N2 of homonicotine may be the reason for its reduced agonist potency. The secondary amine of nornicotine reduces the alkalinity and the probability of making a cation-p interaction with the receptor. The conjugative effect of the lone pair of electrons on the pyrrolidine N2 of (S)-cotinine to the p bond of carbonyl group, causes the pyrrolidine N2 to be hardly protonated, which significantly limits the cation-p interaction with the aromatic cage from the receptor and its action as an agonist.
Piperidine ring derivatives
The N-methyl pyrrolidine moiety was replaced by an N-methyl piperidine ring in nicotine structure to study the effect of increasing the membrane ring on the stimulatory activity of Asu-ACR-16. We found that N-methyl anabasine was inactive, but when the Nmethyl group of the piperidine moiety was removed, the compound was a potent agonist. The piperidine ring of (S)-anabasine may have sterically and electrostatically stabilized the aromatic cage on the receptor better than the N-methylated pyrrolidine ring of nicotine. The novel lead compound, (S)-5-ethynyl-anabasine contains two moieties favorable to the Asu-ACR-16 ligand-binding site: an electron-withdrawing group at the 5-pyridine of nicotine moiety ((S)eSIB 1508Y) and; the piperidine moiety ((S)-anabasine).
(S)-5-ethynyl-anabasine shows high potency (EC 50 0.14 ± 0.01 mM, N ¼ 5) as an agonist.
Docking study as a probe for searching potent Asu-ACR-16 agonist
The potency (EC 50 ) of the selected nicotinic alkaloids was correlated more with the binding affinity in the apo model of Asu-ACR-16 than with the agonist-or antagonist-bound model of Asu-ACR-16. This appears to be due to the different conformation changes of vicinal cysteines or the opened-up orientation of W79 in the agonist-bound and antagonist-bound models of Asu-ACR-16, which reduces the cation-p interaction between W79 and nicotine N2 (Blum et al., 2010; Van Arnam and Dougherty, 2014) . The statistical correlation between the predicted ligand binding affinities in the apo model of Asu-ACR-16 and their corresponding potencies (EC 50 ), suggests that the apo model would be more helpful when searching for potent agonists by docking.
Conclusion
We used structural models of the ECD-Asu-ACR-16 agonistbinding site and expressed receptor to study the structureactivity relationships of several nicotine alkaloids on Asu-ACR-16 receptor. We synthesized a novel compound, (S)-5-ethynyl-anabasine, which was 44 times more potent than (S)-nicotine as an Asu-ACR-16 agonist. Our structure-based drug discovery of ACR-16 agonists also suggests several other nicotine alkaloids as leads for further development. 
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